ArticleTherapeutic advances in medical oncology2018

Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes.

Alessia Cavo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.